compound introduction
TAK-448 acetate (MVT-602 acetate) is a potent and full KISS1R agonist with an IC 50 of 460 pM and an EC 50 of 632 pM In Vivo TAK-448 acetate (0.01-3 mg/kg; given i.h.; dosings on day 0 and 28) has greater anti-tumor effects in VCaP xenograft model. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Rat VCaP xenograft androgen-sensitive prostate cancer model (7-week-old rats) Dosage: 0.01, 0.03, 0.3, 3 mg/kg Administration: Given i.h.; dosings on day 0 and 28 Result: Had greater anti-tumor effects in VCaP xenograft model. Form:Solid IC50& Target:IC50: 460 pM (KISS1R), EC50: 632 pM (KISS1R)
